Epigenetic regulation in human melanoma: past and future

The development and progression of melanoma have been attributed to independent or combined genetic and epigenetic events. There has been remarkable progress in understanding melanoma pathogenesis in terms of genetic alterations. However, recent studies have revealed a complex involvement of epigenetic mechanisms in the regulation of gene expression, including methylation, chromatin modification and remodeling, and the diverse activities of non-coding RNAs. The roles of gene methylation and miRNAs have been relatively well studied in melanoma, but other studies have shown that changes in chromatin status and in the differential expression of long non-coding RNAs can lead to altered regulation of key genes. Taken together, they affect the functioning of signaling pathways that influence each other, intersect, and form networks in which local perturbations disturb the activity of the whole system. Here, we focus on how epigenetic events intertwine with these pathways and contribute to the molecular pathogenesis of melanoma.

Chemotactic signaling in mesenchymal cells compared to amoeboid cells

Cell chemotaxis plays a pivotal role in normal development, inflammatory response, injury repair and tissue regeneration in all organisms. It is also a critical contributor to cancer metastasis, altered angiogenesis and neurite growth in disease. The molecular mechanisms regulating chemotaxis are currently being identified and key components may be pertinent therapeutic targets. Although these components appear to be mostly common in various cells, there are important differences in chemotactic signaling networks and signal processing that result in the distinct chemotactic behavior of mesenchymal cells compared to much better studied amoeboid blood cells. These differences are not necessarily predetermined based on cell type, but are rather chosen and exploited by cells to modify their chemotactic behavior based on physical constraints and/or environmental conditions. This results in a specific type of chemotactic migration in mesenchymal cells that can be selectively targeted in disease. Here, we compare the chemotactic behavior, signaling and motility of mesenchymal and amoeboid cells. We suggest that the current model of chemotaxis is applicable for small amoeboid cells but needs to be reconsidered for large mesenchymal cells. We focus on new candidate regulatory molecules and feedback mechanisms that may account for mesenchymal cell type-specific chemotaxis.